B. Witzenbichler et al., VASCULAR ENDOTHELIAL GROWTH FACTOR-C (VEGF-C VEGF-2) PROMOTES ANGIOGENESIS IN THE SETTING OF TISSUE ISCHEMIA/, The American journal of pathology, 153(2), 1998, pp. 381-394
Recently, vascular endothelial growth factor-C (VEGF-C or VEGF-2) was
described as a specific ligand for the endothelial receptor tyrosine k
inases VEGFR-2 and VEGFR-3. In vivo data, limited to constitutive over
expression in transgenic mice, have been interpreted as evidence that
the growth-promoting effects of VEGF-C are restricted to development o
f the lymphatic vasculature. The current studies were designed to test
the hypothesis that constitutive expression of VEGF-C in adult animal
s promotes angiogenesis. In vitro, VEGF-C exhibited a dose-dependent m
itogenic and chemotactic effect on endothelial cells, particularly for
microvascular endothelial cells (72% and 95% potency, respectively, c
ompared with VEGF-A/VEGF-1) VEGF-C stimulated release of nitric oxide
from endothelial cells and increased vascular permeability in the Mile
s assay; the latter effect was attenuated by pretreatment with the nit
ric oxide synthase inhibitor N-omega-nitro-L-arginine methyl ester. Bo
th VEGFR-2 and VEGFR-3 receptors were shown to be expressed in human s
aphenous vein and internal mammary artery. The potential for VEGF-C to
promote angiogenesis in vivo was then tested In. a rabbit ischemic hi
ndlimb model. Ten days after ligation of the external iliac artery, VE
GF-C was administered as naked plasmid DNA (pcVEGF-C; 500 mu g) from t
he polymer coating of an angioplasty balloon (n = 8 each) or as recomb
inant human protein (rhVEGF-C; 500 mu g) by direct intra-arterial infu
sion. Physiological and anatomical assessments of angiogenesis 30 days
later showed evidence of therapeutic angiogenesis for both pcVEGF-C a
nd rhVEGF-C, Hindlimb blood pressure ratio (ischemic/normal) after pcV
EGF-C increased to 0.83 +/- 0.03 after pcVEGF-C versus 0.59 +/- 0.04 (
P < 0.005) in pGSVLacZ controls and to 0.76 +/- 0.04 after rhVEGF-C ve
rsus 0.58 +/- 0.03 (P < 0.01) in control rabbits receiving rabbit seru
m albumin. Doppler-derived iliac flow reserve was 2.7 +/- 0.1 versus 2
.0 +/- 0.2 (P < 0.05) for pcVEGF-C versus LacZ controls and 2.9 +/- 0.
3 versus 2.1 +/- 0.2 (P < 0.05) for rhVEGF-C versus albumin controls.
Neovascularity was documented by angiography in vivo (angiographic sca
res: 0.85 +/- 0.05 versus 0.51 +/- 0.02 (P < 0.001) for plasmid DNA an
d 0.74 +/- 0.08 versus 0.53 +/- 0.03 (P < 0.05) for protein), and capi
llary density (per mm(2)) was measured at necropsy (252 +/- 12 versus
183 +/- 10 (P < 0.005) for plasmid DNA and 229 a 20 versus 164 +/- 20
(P < 0.05) for protein), In contrast to the results of gene targeting
experiments, constitutive expression of VEGF-C in adult animals promot
es angiogenesis in the setting of limb ischemia, VEGF-C and its recept
ors thus constitute an apparently redundant pathway for postnatal angi
ogenesis and may represent an alternative to VEGF-A for strategies of
therapeutic angiogenesis in patients with limb and/or myocardial ische
mia.